Advertisement

Digestive Diseases and Sciences

, Volume 53, Issue 4, pp 1161–1162 | Cite as

Author’s Response to Letter to the Editor

  • Vasundhara Tolia
Article
  • 38 Downloads

To the Editor,

We appreciate the interest of Drs. Hassall and Owen in our article and are happy to clarify their concerns regarding our report [1]. The questions put forth are made based on their personal observations in management of patients.

Gastroesophageal reflux disease (GERD) and Helicobacter pylori (Hp) are two major research topics of interest to us, hence we routinely evaluate all gastric biopsies for the presence of inflammation, parietal cell hyperplasia and enterochromaffin-cell-like cell (ECL) hyperplasia, Hp density of colonization, and other relevant findings [2]. Stomach biopsies were routinely reviewed by experienced pathologists at Children’s Hospital of Michigan (CHM). When asked specifically about ECL hyperplasia, the Chief of Pathology assured me that it is possible to evaluate for the presence of this finding on routine stains and that special stains are performed for further evaluation if needed. We respect their judgment and expertise regarding this evaluation...

Keywords

Esophagitis Gastroesophageal Reflux Disease Erosive Esophagitis Major Research Topic Refractory GERD 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Tolia V, Boyer K (2008) Long-term proton pump inhibitor use in children: a retrospective review of safety. Dig Dis Sci 53:385–393. Epub 2007 Aug 4PubMedCrossRefGoogle Scholar
  2. 2.
    Dixon MF, Genta RM, Yardley JH, Correa P (1996) Classification and grading of gastritis. Am J Surg Pathol 20:1161–1181PubMedCrossRefGoogle Scholar
  3. 3.
    Graeme-Cook F (2004) Neuroendocrine tumors of the GI tract and appendix. In: Odze RD, Goldblum JR, Crawford JM (eds) Surgical pathology of the GI tract, liver, biliary tract and pancreas. Elsevier, pp 483–504Google Scholar
  4. 4.
    Onimoe GI, Tolia V, Thomas R (2005) Clinical presentation and long term outcome of gastroesophageal reflux disease in children and adolescents. J Pediatr Gastroenterol Nutr 41(4):A34Google Scholar
  5. 5.
    Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R (2004) Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 8:656–664CrossRefGoogle Scholar
  6. 6.
    Kay M, Wyllie R (2006) Esophagogastroduodenoscopy, colonoscopy and related techniques. In: Hyams J, Wyllie R (eds) Pediatric gastrointestinal and liver disease. Pathophysiology/Diagnosis/Management, 3rd edn. Elsevier, pp 1251–1289Google Scholar
  7. 7.
    El-Serag HB, Bailey NR, Gilger M, Rabeneck L (2002) Endoscopic manifestations of gastroesophageal reflux disease in patients between 18 months and 25 years without neurological deficits. Am J Gastroenterol 97:1635–1639PubMedCrossRefGoogle Scholar
  8. 8.
    Hassall E, Kerr W, El-Serag HB (2007) Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr 150:262–267PubMedCrossRefGoogle Scholar
  9. 9.
    Fass R (2007) Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol 41:131–137PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Department of Pediatrics, Providence HospitalMichigan State UniversitySouthfieldUSA

Personalised recommendations